Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Tamiflu “Re-Launch” Seeks To Bolster Seasonal Demand

This article was originally published in The Pink Sheet Daily

Executive Summary

Market research found that unprompted awareness of the antiviral was low, despite having strong publicity for use in pandemic preparedness.

You may also be interested in...



Tamiflu U.S. Labeling Adopts Japanese Warnings

Neuropsychiatric adverse event reports for Roche's antiviral jump in most recent review, prompting FDA staff to suggest a labeling change.

Tamiflu U.S. Labeling Adopts Japanese Warnings

Neuropsychiatric adverse event reports for Roche's antiviral jump in most recent review, prompting FDA staff to suggest a labeling change.

Tamiflu U.S. Labeling Adopts Japanese Warnings

A spike in the number of postmarketing adverse event reports associated with Tamiflu use is prompting FDA staff to recommend adoption of international labeling for the antiviral

Related Content

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel